From diabetes to heart failure: sodium-glucose transporter type 2 inhibitors, the new therapeutic option

Article Sidebar

PDF (Español (España))
Published: Jul 9, 2021

Main Article Content

Gustavo Escalada Lesme
Ministerio de Salud Pública y Bienestar Social, Centro Médico Nacional, Hospital Nacional, Dirección de Cardiología, Servicio de Cardiología. Asunción, Paraguay
https://orcid.org/0000-0001-9998-2048

Article Details

How to Cite
1.
Escalada Lesme G. From diabetes to heart failure: sodium-glucose transporter type 2 inhibitors, the new therapeutic option. Rev. Nac. (Itauguá) [Internet]. 2021 Jul. 9 [cited 2024 Oct. 31];12(2):130-2. Available from: https://revistadelnacional.com.py/index.php/inicio/article/view/32
Issue
Vol. 12 No. 2 (2020): July-December
Section
Cartas al Editor
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128. doi: 10.1056/NEJMoa1504720.

Neal B, Perkoviv V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-657. doi: 10.1056/NEJMoa1611925.

McMurray JJV, DeMets DL, Inzucchi SE, Købe L, Kosiborod MN, Langkilde AM, et al. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail. 2019;21(5):665-675. doi: 10.1002/ejhf.1432.

Packer M, Anker SD, Butler J, Filippatos G, Pocock J, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure [published online ahead of print, 2020 Aug 29]. N Engl J Med. 2020 Aug 29. doi: 10.1056/NEJMoa2022190.

Anguita M, Batés Genís A, Cepeda JM, Cinza S, Cosín J, Crespo Leiro M, et al. Consenso de expertos sobre insuficiencia cardiaca con fracción de eyección reducida: más allá de las guías. Rev Esp. Cardiol. Supl. 2020;20(B):1-46. Disponible en: https://www.revespcardiol.org/es-pdf-S1131358720300169.